PTGX · Protagonist Therapeutics, Inc
$138.31
+4.04 (+3.01%)
At close · Jul 21
Market Cap
$8.89B
Shares
64.31M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$46.02M
-89.4%
FY2025
Net Income
-$130.15M
-147.3%
FY2025
Operating Margin
-343.63%
-401.8pp
FY2025
Diluted EPS
-$2.05
-148.5%
FY2025
Operating Cash Flow
$57.67M
-68.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $74.06M | $46.02M | $434.43M | $60M | $26.58M | $27.36M | — | $2.72M | $30.93M | — | — | |
| $170.14M | $159.29M | $138.13M | $120.16M | $126.22M | $126.01M | $74.51M | $65M | $59.5M | $46.18M | $25.71M | |
| $46.39M | $44.85M | $43.46M | $33.49M | $31.74M | $27.2M | $18.64M | $15.75M | $13.7M | $11.78M | $6.96M | |
| — | $1.28M | $826K | $977K | $1.03M | $813K | $789K | $703K | $527K | $406K | $317K | |
| $300K | — | — | — | — | $300K | $300K | — | — | — | — | |
| $216.53M | $204.14M | $181.59M | $153.65M | $157.95M | $153.2M | $93.14M | $80.75M | $73.19M | $57.96M | $32.67M | |
| -$142.47M | -$158.13M | $252.84M | -$93.65M | -$131.37M | -$125.85M | -$64.52M | -$80.52M | -$42.27M | -$37.9M | -$32.67M | |
| — | -343.63% | 58.2% | -156.09% | -494.24% | -460.01% | — | -2961.42% | -136.68% | — | — | |
| — | -$156.85M | $253.67M | -$92.68M | -$130.34M | -$125.03M | -$63.73M | -$79.82M | -$41.74M | -$37.49M | -$32.35M | |
| — | — | — | — | $598K | $598K | $598K | $169K | — | — | — | |
| $27.09M | $28.79M | $26.32M | $14.9M | $4.06M | $443K | $900K | $2.81M | $2.55M | $940K | $242K | |
| -$2000 | $27K | $250K | -$201K | -$80K | -$149K | -$46K | -$1000 | -$34K | -$34K | -$34K | |
| -$115.38M | -$129.31M | $279.41M | -$78.96M | -$127.39M | -$125.55M | -$64.85M | -$77.88M | -$39.72M | -$36.96M | — | |
| -$664K | $838K | $4.22M | $0 | $0 | $0 | $1.31M | -$691K | $799K | $0 | $0 | |
| -$114.71M | -$130.15M | $275.19M | -$78.96M | -$127.39M | -$125.55M | -$66.15M | -$77.19M | -$38.92M | -$36.96M | -$37.18M | |
| — | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% | — | -2838.8% | -125.87% | — | — | |
| — | — | — | — | — | — | — | — | -$38.92M | -$36.96M | -$37.74M | |
| -$115.07M | -$129.43M | $275.21M | -$78.7M | -$127.45M | -$125.88M | -$65.9M | -$77.18M | -$39.15M | -$36.72M | -$37.32M | |
| USD/shares | — | -$2.05 | $4.47 | -$1.39 | -$2.60 | — | — | — | — | — | — |
| USD/shares | — | -$2.05 | $4.23 | -$1.39 | -$2.60 | — | — | — | — | — | — |
| shares | — | 63.57M | 61.57M | 56.76M | 49.04M | 46.32M | 34.4M | 25.89M | 22.36M | 17.69M | 6.5M |
| shares | — | 63.57M | 65.08M | 56.76M | 49.04M | 46.32M | 34.4M | 25.89M | 22.36M | 17.69M | 6.5M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Single Reportable Segment | $46,016,000 | $434,433,000 | $60,000,000 | $26,581,000 |
Key facts
CIK
1377121
CUSIP
74366E102
13F (30d)
34 filings
34 filers
Visit website
Investor relations